NeoGenomics (NASDAQ:NEO - Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 0.150-0.190 for the period, compared to the consensus EPS estimate of 0.200. The company issued revenue guidance of $735.0 million-$745.0 million, compared to the consensus revenue estimate of $735.0 million.
Analyst Upgrades and Downgrades
NEO has been the subject of several research analyst reports. Piper Sandler decreased their price objective on shares of NeoGenomics from $21.00 to $18.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Needham & Company LLC decreased their target price on NeoGenomics from $19.00 to $18.00 and set a "buy" rating for the company in a research report on Wednesday, February 19th. The Goldman Sachs Group cut their price target on NeoGenomics from $20.00 to $18.00 and set a "buy" rating on the stock in a research report on Tuesday, January 28th. Benchmark downgraded NeoGenomics from a "buy" rating to a "hold" rating in a report on Monday, January 13th. Finally, Bank of America lowered their target price on shares of NeoGenomics from $19.00 to $16.00 and set a "neutral" rating on the stock in a research report on Wednesday, February 19th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $19.60.
View Our Latest Stock Analysis on NEO
NeoGenomics Stock Performance
Shares of NASDAQ NEO traded down $0.44 during mid-day trading on Friday, hitting $10.10. 1,911,538 shares of the company were exchanged, compared to its average volume of 1,226,512. The company has a quick ratio of 1.91, a current ratio of 1.98 and a debt-to-equity ratio of 0.38. The firm has a market cap of $1.30 billion, a price-to-earnings ratio of -16.29 and a beta of 1.28. The stock has a 50 day simple moving average of $13.79 and a 200-day simple moving average of $15.03. NeoGenomics has a 1-year low of $8.98 and a 1-year high of $19.11.
NeoGenomics (NASDAQ:NEO - Get Free Report) last issued its earnings results on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.05). NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. The firm had revenue of $172.00 million during the quarter, compared to analysts' expectations of $173.40 million. On average, sell-side analysts forecast that NeoGenomics will post -0.2 EPS for the current fiscal year.
About NeoGenomics
(
Get Free Report)
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Recommended Stories
Before you consider NeoGenomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeoGenomics wasn't on the list.
While NeoGenomics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
